Tyra Biosciences (NASDAQ:TYRA) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Tyra Biosciences (NASDAQ:TYRA) released its quarterly earnings data on Monday. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03), FiscalAI reports.

Tyra Biosciences Price Performance

Shares of TYRA stock opened at $33.01 on Wednesday. The stock has a market capitalization of $1.76 billion, a PE ratio of -16.42 and a beta of 1.06. The business’s 50 day simple moving average is $29.72 and its 200 day simple moving average is $20.76. Tyra Biosciences has a one year low of $6.42 and a one year high of $35.71.

Insider Activity

In other news, Director Robert J. More sold 10,000 shares of the company’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $25.00, for a total value of $250,000.00. Following the sale, the director directly owned 3,823,425 shares of the company’s stock, valued at approximately $95,585,625. This represents a 0.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 15.20% of the company’s stock.

Institutional Trading of Tyra Biosciences

Institutional investors have recently bought and sold shares of the company. Corton Capital Inc. acquired a new position in shares of Tyra Biosciences in the 2nd quarter valued at about $233,000. Sio Capital Management LLC increased its holdings in Tyra Biosciences by 94.5% in the second quarter. Sio Capital Management LLC now owns 810,274 shares of the company’s stock worth $7,754,000 after purchasing an additional 393,657 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Tyra Biosciences in the second quarter worth approximately $326,000. Walleye Capital LLC lifted its stake in Tyra Biosciences by 163.2% in the second quarter. Walleye Capital LLC now owns 370,408 shares of the company’s stock valued at $3,545,000 after buying an additional 229,666 shares during the period. Finally, XTX Topco Ltd bought a new position in shares of Tyra Biosciences during the 2nd quarter worth approximately $331,000. Institutional investors own 84.14% of the company’s stock.

Analyst Upgrades and Downgrades

TYRA has been the topic of a number of research reports. Cantor Fitzgerald started coverage on shares of Tyra Biosciences in a research note on Tuesday, February 24th. They set an “overweight” rating on the stock. Jefferies Financial Group lifted their price target on Tyra Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research note on Tuesday, February 3rd. HC Wainwright upped their price objective on Tyra Biosciences from $30.00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Barclays assumed coverage on shares of Tyra Biosciences in a report on Tuesday, January 27th. They issued an “overweight” rating for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $42.33.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.